No coin nor oath required. For personal study only.
The concept of angiogenesis as a target for the treatment of cancer has been considered for many years but only with the biological and molecular identification of one of the key mediators of angiogenesis, vascular endothelial growth factor (VEGF), have clinical trials in this field been truly feasible. Inhibition of VEGF, using antibodies to the ligand, its receptor or inhibitors of VEGF receptor tyrosine kinase (TKIs), leads to pruning of vasculature and 'normalisation' which may lead to increased delivery of more conventional agents. Such changes have been observed both in animal models and in patients using dynamic contrast MRI. An open-label, randomised phase III study (E2100) testing an antibody to VEGF (bevacizumab) in addition to weekly taxol, yielded an improvement in response rate and reduced the risk of disease progression (PFS) by about 50%. No improvement in overall survival was observed. Two subsequent
π SIMILAR VOLUMES
## Abstract We present unsupervised speaker indexing, combined with automatic speech recognition (ASR) for speech archives, such as discussions. Our proposed indexing method is based on anchor models, by which we define a feature vector based on the similarity with speakers of a largeβscale speech